Moderna Announces Encouraging Phase 1/2 Results for Combo Influenza and COVID-19 Vaccine
Moderna, Inc. has announced positive interim findings from its Phase 1/2 trial of mRNA-1083, an innovative dual-purpose vaccine targeting both
Read moreModerna, Inc. has announced positive interim findings from its Phase 1/2 trial of mRNA-1083, an innovative dual-purpose vaccine targeting both
Read moreElly Lilly announced plans to acquire POINT Biopharma, with the strategic move set to boost Lilly’s oncology capabilities with next-generation
Read moreSeelos Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in therapies for central nervous system disorders and rare diseases, has unveiled
Read moreThe Biosimilar Tyruko® has been approved for all indications of reference medicine, as the first and only biosimilar to treat
Read moreOrano Med, a clinical-stage biotechnology company that develops the next generation of targeted therapies against cancer using the unique properties
Read moreULTRAMIC® ceramic heaters from Watlow® are engineered for thermal applications where the high performance of advanced ceramic heaters is required
Read moreThe MANDARA Phase III trial marks the first head-to-head comparison of biologics in treating eosinophilic granulomatosis with polyangiitis (EGPA), putting
Read moreThe partnership with Samsung Bioepis Grants Novartis’ generic-drugs unit Sandoz exclusive commercialization rights for biosimilar SB17 Ustekinumab in Europe and
Read moreThe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommendation is grounded in pre-clinical
Read moreStressMarq manufactures and offers a comprehensive range of Alzheimer’s Disease Research Products. StressMarq’s product range includes Antibodies, Proteins, Immunoassays, Small
Read more